Perspective Therapeutics, Inc. short interest in 2026
In 2026, Perspective Therapeutics, Inc.'s disclosed short interest ran from 11.05% of shares outstanding on 15 Jan 2026 to 19.98% on 15 Sep 2026, a change of +8.93 percentage points. The year's high was 20.60% on 31 Jul 2026 and its low 8.86% on 13 Mar 2026, averaging 14.70% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 25.65 days on 31 Jul 2026. Full history: Perspective Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 11.05% (15 Jan 2026)
- End of year
- 19.98% (15 Sep 2026)
- Change
- +8.93 pp
- High
- 20.60% (31 Jul 2026)
- Low
- 8.86% (13 Mar 2026)
- Average
- 14.70%
- Highest days to cover
- 25.65 (31 Jul 2026)
- SEC filings marked
- 9
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 11.05% | 5.33 | results (8-K) |
| 30 Jan 2026 | 12.83% | 1.01 | |
| 13 Feb 2026 | 12.93% | 1.97 | results (8-K) |
| 27 Feb 2026 | 12.97% | 4.53 | |
| 13 Mar 2026 | 8.86% | 7.83 | |
| 31 Mar 2026 | 12.40% | 7.26 | 10-K filed, results (8-K) |
| 15 Apr 2026 | 12.00% | 17.99 | |
| 30 Apr 2026 | 11.41% | 8.43 | |
| 15 May 2026 | 11.07% | 7.96 | results (8-K), 10-Q filed, results (8-K) |
| 29 May 2026 | 11.20% | 11.31 | |
| 15 Jun 2026 | 11.97% | 8.99 | |
| 30 Jun 2026 | 19.95% | 7.28 | |
| 15 Jul 2026 | 20.00% | 10.01 | |
| 31 Jul 2026 | 20.60% | 25.65 | |
| 14 Aug 2026 | 20.18% | 18.22 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 20.46% | 23.64 | |
| 15 Sep 2026 | 19.98% | 16.85 |
See also: Perspective Therapeutics, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.